Shareholders paid significantly for being loose with the checkbook. 9% of current MC last fin yr. Source: FY22 Annual Report
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling